1. A Phase II Trial of Bevacizumab in Patients with Recurrent/Progressive Solid Tumor Brain Metastases That Have Progressed Following Whole-Brain Radiation Therapy.
- Author
-
Dixit, Karan, Singer, Lauren, Grimm, Sean Aaron, Lukas, Rimas V., Schwartz, Margaret A., Rademaker, Alfred, Zhang, Hui, Kocherginsky, Masha, Chernet, Sofia, Sharp, Laura, Nelson, Valerie, Raizer, Jeffrey J., and Kumthekar, Priya
- Subjects
ADENOCARCINOMA ,RADIOTHERAPY ,PATIENT safety ,RESEARCH funding ,BEVACIZUMAB ,CLINICAL trials ,BREAST tumors ,PAPILLARY carcinoma ,LYMPHOPENIA ,HYPERTENSION ,TREATMENT effectiveness ,METASTASIS ,DRUG efficacy ,QUALITY of life ,NEUROENDOCRINE tumors ,THROMBOEMBOLISM ,SURVIVAL analysis (Biometry) ,PROGRESSION-free survival ,LUNG cancer ,BRAIN tumors ,DRUG tolerance ,OVERALL survival ,EVALUATION - Abstract
Simple Summary: For patients with solid tumor brain metastases that progress after whole-brain radiotherapy, there are limited treatment options. The aim of our prospective trial was to examine the usage of bevacizumab as salvage therapy in this specific patient population, with primary endpoints being radiologic response, survival, safety, and quality of life. Our data show that bevacizumab was well tolerated, maintained quality of life, and improved overall survival with radiologic response. Patients with solid tumor brain metastases that progress after whole-brain radiation have limited options. This prospective trial investigated the efficacy, safety, and tolerability of bevacizumab as salvage therapy in this population. Eligible patients received bevacizumab 10 mg/kg intravenously every 2 weeks until progression. The primary endpoint was radiologic response using Response Assessment in Neuro-Oncology (RANO) criteria. The secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response, and safety. Quality of life (QOL) was studied using the Functional Assessment of Cancer Therapy-Brain (FACT-Br) scale. Twenty-seven patients were enrolled, with twenty-four having evaluable data for response. The majority of histologies (n = 21, 78%) were breast cancer. The remaining histologies were non-small-cell lung cancer (n = 4, 15%), neuroendocrine cancer (n = 1, 3%), and papillary fallopian serous adenocarcinoma (n = 1, 3%). Eighteen patients had radiologic response, with two patients demonstrating partial response (8.33%) and sixteen patients demonstrating stable disease (66.7%). The median duration of response was 203 days. PFS at 6 months was 46%, median PFS was 5.3 m, and median OS was 9.5 m. Treatment was well tolerated, with six patients experiencing grade 3 lymphopenia and hypertension. There was one grade 3 thromboembolism. QOL was not negatively impacted. Bevacizumab is a safe and feasible salvage treatment with durable response and favorable overall survival for patients with progressive brain metastases after whole-brain radiation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF